¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦7Â÷ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ °æÀÎÁöȸ ½ÉÆ÷Áö¾ö : 2023-09-09

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦7Â÷ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ °æÀÎÁöȸ ½ÉÆ÷Áö¾ö : 2023-09-09
±³À°ÀÏÀÚ : 2023-09-09
±³À°Àå¼Ò : °¡Å縯°üµ¿´ëÇб³ ±¹Á¦¼º¸ðº´¿ø, ¸¶¸®¾ÆȦ(3F)

±³À°ÁÖÁ¦ : Á¦7Â÷ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ °æÀÎÁöȸ ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : °æÀÎÁöȸ

´ã´çÀÚ : Á¶¿¹¸®
¿¬¶ôó : 02-582-8222

À̸ÞÀÏ : yehc@kscvi.org

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ÀÎõ±¤¿ª½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù.


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:00~09:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) The Anterograde Approach for CTO(Chronic Total Occlusion) À̿뱸(ÇѾçÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:10~09:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) The Retrograde Approach for CTO(Chronic Total Occlusion) ¼­Á¸(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:20~09:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Novel Devices for CTO(Chronic Total Occlusion) including Catheters and Wires ¼­¿ë¼º(¸íÁöº´¿ø)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:30~09:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) The Role of DCB(Drug-coated Balloon) for CTO(Chronic Total Occlusion) ±è¼±¿ø(°í·ÁÀÇ´ë)

Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 09:40~10:00 Discussion ()

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:00~10:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Step-by-Step: When and How to Deploy Two Stents in a Bifurcation Lesion À念¿ì(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:10~10:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Step-by-Step: Rotablator Use in Severely Calcified Lesions ¹ÚÇüº¹(°¡Å縯°üµ¿ÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:20~10:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Step-by-step: How to Treat Lesions with Stent Restenosis or Thrombosis À̽·ü(Â÷ÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:30~10:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Reimbursement Rejection Experiences in CHIP PCI(High Risk Percutaneous Coronary Intervention) ÀÌÇöÁ¾(ºÎõ¼¼Á¾º´¿ø)

Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 10:40~11:00 Discussion ()

ÈÞ½Ä 09¿ù 09ÀÏ 11:00~11:10 Coffee Break ()

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:10~11:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Vulnerable Plaque Identification by Imaging Modality ¹ÚÁ¾°ü(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:20~11:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Intravascular Imaging–Guided Complex PCI(Percutaneous Coronary Intervention), lesson from RENOVATE Trial ÀÌÁÖ¸í(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:30~11:40 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Angiography-based FFR(Fractional Flow Reserve): From Clinical Evidence to Daily Practice ±âÀ¯Á¤(À»ÁöÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:40~11:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Non Hyperemic Pressure Ratio(NHPR) Guided PCI(Percutaneous Coronary Intervention) Àü±âÇö(¼­¿ïÀÇ´ë)

Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 11:50~12:10 Discussion ()

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 12:10~12:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) How to Apply Non-Hyperemic Indices in Our Practice ÀÌÇöÁ¾(ºÎõ¼¼Á¾º´¿ø)

±âŸ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 12:20~12:35 ³»°¡ °É¾î¿Â ±æ Àå¾ç¼ö(Â÷ÀÇ´ë)

Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 12:35~12:45 Discussion ()

±âŸ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 12:45~12:55 °æÀÎÁöȸ ÃÑȸ ()

½Ä»ç 09¿ù 09ÀÏ 12:55~13:40 Lunch Break ()

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 13:40~13:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Patients Selection for Protected PCI(Percutaneous Coronary Intervention): Who Benfit the Most? °ø¹Î±Ô(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 13:50~14:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) IABP(Intra-aortic Balloon Pump): Clinical Evidence in High Risk PCI(Percutaneous Coronary Intervention) ±èÁ¦»ó(µ¿±¹ÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:00~14:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) VA-ECMO(Veno-Arterial Extracorporeal membrane oxygenation): Clinical Evidence in High Risk PCI(Percutaneous Coronary Intervention) Á¶Çü¿ø(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:10~14:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Impella: Clinical Evidence in High Risk PCI(Percutaneous Coronary Intervention) ÀåÁö¿ë(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø)

Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:20~14:40 Discussion ()

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:40~14:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) My Wire Selection and Escalation Strategies in CLTI(Chronic Limb-Threatening Ischemia) ¹ÚÇö¿ì(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 14:50~15:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Vessel Prep in Severe Calcification ¹Ú»óµ·(ÀÎÇÏÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 15:00~15:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Drug Delivery and Outcomes in Calcified Lesions ±è¼¼ÈÆ(ÀÎõ¼¼Á¾º´¿ø)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 15:10~15:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Endovascular Repair of Chronic Type B Aortic Dissection °­¼¼ÈÆ(Â÷ÀÇ´ë)

Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 15:20~15:40 Discussion ()

ÈÞ½Ä 09¿ù 09ÀÏ 15:40~15:50 Coffee Break ()

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 15:50~16:00 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Valve-in-valve TAVR(Transcatheter Aortic Valve Replacement) ¹ÚÇÏ¿í(ºÎõ¼¼Á¾º´¿ø)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:00~16:10 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Expanding Indication of TAVR(Transcatheter Aortic Valve Replacement) ¹®À翬(Â÷ÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:10~16:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Novel Trends in PFO(Patent Foramen Ovale) ÀÌ»ó¿±(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:20~16:30 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) USE of ICE(Intracardiac echocardiography) in Structural Heart Disease °­¿õö(°¡ÃµÀÇ´ë)

Åä·Ð 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:30~16:50 Discussion ()

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 16:50~17:05 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Relapsed NSTEMI due to Acute Gastrointestinal Bleeding after NSTEMI ¿À½Â¿í(°¡Å縯°üµ¿ÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 17:05~17:20 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) My First Case of Retrograde CTO(Chronic Total Occlusion) PCI(Percutaneous Coronary Intervention) ¹Î´Ù´Ï¿¤(±ºÆ÷Áö»ùº´¿ø)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 17:20~17:35 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Cases of Coronary Perforation ±è»óÈÆ(Â÷ÀÇ´ë)

±³À°½Ã°£ 09¿ù 09ÀÏ ¸¶¸®¾ÆȦ(3F) 17:35~17:50 (ÃÊ·Ï¡¤±¸¿¬ ¹ßÇ¥) Acute Myocardial Infarction Patient with Severe Thrombocytopenia ÃÖ¼ºÈ¯(ÀÎÇÏÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦7Â÷ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ °æÀÎÁöȸ ½ÉÆ÷Áö¾ö : 2023-09-09""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â Á¦12ȸ ´ëÇÑôÃßÁ¾¾çÇÐȸ Ãß°èÇмú´ëȸ : 2023-09-09
´ÙÀ½±Û ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2023 Áöȸ&ÁöºÎ ½ÉÆ÷Áö¾ö-Á¦ÁÖ : 2023-09-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 10 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 15 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 8 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 5 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 7 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 8 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 3 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 1 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 2 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 4 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 5 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 3 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 4 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 4 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 7 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷